9 results
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... cytochrome p450 CYP3A4 ... substrates to CYP3A4 ... Chemotherapy #Oncology #Hematology ... Interactions #Table #Pharmacology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... of cancer-associated ... thrombosis; PE = pulmonary ... Anticoagulation #Management ... #Hematology #Oncology
Pharmacologic treatment algorithms by Global Initiative for Chronic Obstructive Lung Disease grade. Highlighted boxes and arrows
Pharmacologic treatment ... indicate preferred treatment ... limitation, further evaluation ... #Management #Pulmonary
Adult-Onset Still's Disease
Clinical triad: Fever, Arthralgia/arthritis, Skin rash ± odynophagia
+ Biological inflammation: Increased neutrophils, Hyperferritinemia, decreased
hemopathies, solid cancers ... hepatitis • Pulmonary ... Disease #diagnosis #management ... #treatment #rheumatology
Eosinophilic Gastroenteritis: Treatment Options Based on Severity of the Disease
Mild:
 • Trial of PPI
 • Trial
Gastroenteritis: Treatment ... strictures Severe + Concern ... for HES: • Hematology ... consult for evaluation ... #management #gastroenterology
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
B-LNH), solid cancers ... Unknown cause Treatment ... Lymphohistiocytosis #diagnosis #management ... #treatment #summary ... #rheumatology
Pulmonary Nodule
Evaluation is guided by nodule size & assessment of probability of malignancy. In addition is
Pulmonary Nodule ... Evaluation is guided ... The treatment of ... Management options ... diagnosis of lung cancer
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
, INC risk PE, Pulmonary ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... Sjogrens #Syndrome #Rheumatology ... #Diagnosis #Management
Myelodysplastic syndromes current treatment algorithm 2018.

From Blood Cancer Journal, Published 24 May 2018

Myelodysplastic syndromes (MDS) are
syndromes current treatment ... risk of clonal evolution ... influence outcomes and treatment ... cardiovascular or pulmonary ... #algorithm #hematology